Overview

Reducing Port Access Pain and Clinic Wait Time: An Evaluation of EMLA Cream Versus nüm™ Vapocoolant Spray

Status:
Enrolling by invitation

Trial end date:
2024-08-01

Target enrollment:
0

Participant gender:
All

Summary

The goal of this clinical trial is to compare a sterile vapocoolant spray to EMLA cream in children with access ports. Participants will receive either the spray or cream prior to port access and rate pain on a scale. Researchers will compare spray vs cream to see if the spray is as effective as the cream in reducing pain associated with port puncture.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Marianne Hutti

Collaborator:

Bimeco Group

Treatments:

Lidocaine, Prilocaine Drug Combination

Criteria

Inclusion Criteria:

- English-speaking

- Present appointment is for drawing blood, receiving intravenous antibiotics, blood
products, or chemotherapy

- EMLA cream has (standard of care) or has not (vapocoolant) been applied to the port
site prior to the appointment

- Previous allergic reaction or skin irritation due to EMLA

- Quick access to the child's port is needed for drawing blood, or giving treatments,
blood products, or drugs such as chemotherapy

Exclusion Criteria:

- Child has a legal guardian or non-parent family member as the only adult with them for
the visit.

- Children less than 4 years of age

- Children with altered mental status

- History of traumatic brain injury, developmental delay or autism

- Child is nonverbal

- Present appointment is for drawing blood, receiving intravenous antibiotics, blood
products, or chemotherapy, and child and parents prefer to wait for EMLA cream to take
effect.